Table I.
AZA | LDara-C | |
---|---|---|
Parameter | N = 45 | N = 49 |
Median age, years (range) | 69·0 (42–82) | 71·0 (56–85) |
Age categories, n (%) | ||
<65 years | 14 (31) | 7 (14) |
65–74 years | 21 (47) | 28 (57) |
≥75 years | 10 (22) | 14 (29) |
Male gender – n (%) | 39 (87) | 35 (71) |
FAB Classification – n (%) | ||
RAEB | 27 (60) | 25 (51) |
RAEB-t | 15 (33) | 19 (39) |
CMML | 1 (2·2) | 1 (2·0) |
AML | 1 (2·2) | 0 |
MPD | 0 | 1 (2·0) |
Indeterminate | 1 (2·2) | 3 (6·1) |
IPSS – n (%) | ||
Intermediate-1 | 1 (2·2) | 2 (4·1) |
Intermediate-2 | 22 (49) | 21 (43) |
High | 19 (42) | 21 (43) |
Indeterminate | 2 (4·4) | 4 (8·2) |
Not applicable★ | 1 (2·2) | 1 (2·0) |
ECOG Status – n (%) | ||
Grade 0 | 21 (47) | 29 (59) |
Grade 1 | 21 (47) | 17 (35) |
Grade 2 | 1 (2) | 2 (4) |
Missing | 2 (4) | 1 (2) |
# RBC transfusions – median (range) during the 56 d prior to study enrollment | 2·0 (0–9) | 1·0 (0–10) |
Hb (g/l) – median (range) | 96 (71–122) | 97 (54–143) |
Platelet count (109/l) – median (range) | 42 (7–252) | 84 (18–437) |
ANC (109/l) – median (range) | 0·8 (0–7·9) | 1·3 (0·2–18·7) |
FAB, French-American- British; RAEB, refractory anaemia with excess blasts; RAEB-t, RAEB in transformation; CMML, chronic myelo-monocytic leukaemia; AML, acute myeoid leukaemia; MPD, myelo-proliferative disease; IPSS, International Prognostic Scoring System; ECOG, Eastern Cooperative Oncology Group; RBC, red blood cell; Hb, haemoglobin; ANC, absolute neutrophil count.
IPSS classification was not applicable for patients who were classified as AML or MPD (per the FAB classification) because the IPSS classification was not developed for those patients.